IP Library Granted Patent US 10,386,368
Granted Patent B2
US 10,386,368 · App. 15/902,614 · Granted Aug 20, 2019

Isolation of human lung progenitors derived from pluripotent stem cells

Inventors: Darrell N. Kotton (Newton, MA); Finn Hawkins (Boston, MA)
Assignee: TRUSTEES OF BOSTON UNIVERSITY
G01N33/56966A61K9/007A61K35/42C12N5/0689C12N2501/117C12N2501/119C12N2501/155C12N2501/999C12N2506/04C12N2506/45G01N2333/4703G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,386,368
App. No.
15/902,614
Granted
Aug 20, 2019
Kind
B2
Abstract

Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

Claims (13)

1. A method for isolating a lung progenitor cell, the method comprising:

(a) contacting a population of cells comprising lung primordial progenitor cells with an antibody that recognizes CD47 and a second antibody that recognizes CD26 to determine the level of expression of CD47 and CD26, and

(b) isolating at least one cell with a cell surface phenotype comprising a CD47 expression level that is at least 20% greater than the CD47 expression level in a control cell and comprising a CD26 expression level that is at least 20% lower than the CD26 expression level in a control cell,

wherein the control cell is a cell that is not committed to the lung lineage,

thereby isolating a CD47 hi /CD26 lo lung progenitor cell from the population of cells comprising lung primordial progenitor cells.

2. The method of claim 1 , where the lung progenitor cell also expresses NKX2-1.

3. The method of claim 1 , wherein the lung progenitor cell can be separated from neuronal cell precursors by measuring increased expression of one or more transcriptional markers selected from the group consisting of: GRHL2, ELF3, GATA6, HNF1B, HOXA1 and FOXA1.

4. The method of claim 1 , wherein the lung progenitor cell further expresses SFTA3, CPM, NFIB, NKX2-1, CRH, JUN, MECOM, SOX2, HES1, HOXA1, FOXA2, FOXA1, GATA6, GRHL2, IRX1, IRX2, ELF3, ELF5, HNFIB, FOXP2, HOXA4, HOXC4, SHH, EPCAM, CD166, CD227, SOX2, SOX9, and/or LAMA2.

5. The method of claim 1 , wherein the lung progenitor cell expresses NKX2-1, SFTA3, CPM, and LAMA3.

6. The method of claim 1 , wherein the lung progenitor cell does not express SCGB3A2, SFTPB, TP63, ICAM1, IL8, ASCL1, FOXJ1, SCGB1A1, ITGB6, SIX3, SIX6, OTX1 or PAX8.

7. The method of claim 1 , wherein the population of cells comprising lung primordial progenitor cells is cultured in vitro without mesenchymal co-culture support.

8. The method of claim 1 , wherein the lung primordial progenitor cells are produced by culturing anterior foregut endoderm cells in the presence of CHIR99021, FGF10, KGF, BMP4 and retinoic acid.

9. The method of claim 1 , wherein the cell that is not committed to the lung lineage comprises a thyroid progenitor cell, a neuronal progenitor cell or a lung primordial progenitor cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 10, 2020
From: BOSTON UNIVERSITY MEDICAL CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 051769/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2019
From: KOTTON, DARRELL N.; HAWKINS, FINN
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 048907/0909 →
Continuity (2)
Provisional Application 62463184 · Feb 24, 2017
Related Publication 20180246099A1 · Aug 30, 2018